![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 7, 5529-5540, February 15, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Ligand-receptor coupling is one of the important
constituents of signal transduction and is essential for physiological
transmission of actions of endogenous substances including steroid
hormones. However, molecular mechanisms of the redundancy between
glucocorticoid and mineralocorticoid actions remain unknown because of
complicated cross-talk among, for example, these adrenal steroids,
their cognate receptors, and target genes. Receptor-specific ligand
that can distinctly modulate target gene expression should be developed to overcome this issue. In this report, we showed that a
pyrazolosteroid cortivazol (CVZ) does not induce either nuclear
translocation or transactivation function of the mineralocorticoid
receptor (MR) but does both for the glucocorticoid receptor (GR).
Moreover, deletion analysis of the C-terminal end of the GR has
revealed that CVZ interacts with the distinct portion of the ligand
binding domain (LBD) and differentially modulates the
ligand-dependent interaction between transcription
intermediary factor 2 and the LBD when compared with cortisol,
dexamethasone, and aldosterone. Thus, it is indicated that CVZ may not
be only a molecular probe for the analysis of the redundancy between
the GR and MR in vivo but also a useful reagent to clarify
structure-function relationship of the GR LBD.
Distinct Interaction of Cortivazol with the Ligand
Binding Domain Confers Glucocorticoid Receptor Specificity
CORTIVAZOL IS A SPECIFIC LIGAND FOR THE GLUCOCORTICOID
RECEPTOR*
§,
,
,
¶
Division of Clinical Immunology, Advanced
Clinical Research Center, Institute of Medical Science, University of
Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 and
§ Second Department of Internal Medicine, Asahikawa Medical
College, 2-1-1 Midorigaoka-higashi, Asahikawa 078-0083, Japan
*
This work was supported in part by the grants from the
Ministry of Education, Science, Technology, Sports, and Culture, the Ministry of Health, Labor, and Welfare, the Takeda Science Foundation, Suzuken Memorial Foundation, and the Cell Science Research Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article has been cited by other articles:
![]() |
S. Sola, J. D. Amaral, P. M. Borralho, R. M. Ramalho, R. E. Castro, M. M. Aranha, C. J. Steer, and C. M. P. Rodrigues Functional Modulation of Nuclear Steroid Receptors by Tauroursodeoxycholic Acid Reduces Amyloid {beta}-Peptide-Induced Apoptosis Mol. Endocrinol., October 1, 2006; 20(10): 2292 - 2303. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shimizu, R. Ouchida, N. Yoshikawa, T. Hisada, H. Watanabe, K. Okamoto, M. Kusuhara, H. Handa, C. Morimoto, and H. Tanaka HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b PNAS, June 14, 2005; 102(24): 8555 - 8560. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yoshikawa, K. Yamamoto, N. Shimizu, S. Yamada, C. Morimoto, and H. Tanaka The Distinct Agonistic Properties of the Phenylpyrazolosteroid Cortivazol Reveal Interdomain Communication within the Glucocorticoid Receptor Mol. Endocrinol., May 1, 2005; 19(5): 1110 - 1124. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kodama, N. Shimizu, N. Yoshikawa, Y. Makino, R. Ouchida, K. Okamoto, T. Hisada, H. Nakamura, C. Morimoto, and H. Tanaka Role of the Glucocorticoid Receptor for Regulation of Hypoxia-dependent Gene Expression J. Biol. Chem., August 29, 2003; 278(35): 33384 - 33391. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |